Antiarrhythmic therapy can be provided safely in ESRD patients, but requires meticulous attention to detail due to metabolic alterations and drug interactions.
Summary Patients with ESRD have arrhythmias similar to those in patients without renal complications. It is unclear whether ESRD itself is a risk factor for the development of arrhythmias or whether it is simply a marker for other diseases which predispose to arrhythmias. Regardless, therapy can be undertaken but special caution is required because of metabolic alterations and drug interactions which can make antiarrhythmic therapy more risky than in the general population. With meticulous attention to detail, therapy can be provided safely.
No takes yet. Share an insight, caveat, or question.
Epstein et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: